Frequently, drug development has focused on minute molecules, but peptide collaborations are rapidly gaining attention. This new approach embraces combining peptidic sequences with other biological modalities to tackle challenging illness pathways. By employing the distinctive characteristics of peptides – such as high selectivity and delivery �